These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9350918)

  • 1. HMG-CoA reductase inhibitors: a new class of anti-inflammatory drugs?
    Rossen RD
    J Am Coll Cardiol; 1997 Nov; 30(5):1218-9. PubMed ID: 9350918
    [No Abstract]   [Full Text] [Related]  

  • 2. HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
    Teupser D; Bruegel M; Stein O; Stein Y; Thiery J
    Biochem Biophys Res Commun; 2001 Dec; 289(4):838-44. PubMed ID: 11735122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
    Weber C; Erl W; Weber KS; Weber PC
    J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
    Stalker TJ; Lefer AM; Scalia R
    Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway.
    Hiraoka M; Nitta N; Nagai M; Shimokado K; Yoshida M
    Life Sci; 2004 Jul; 75(11):1333-41. PubMed ID: 15234191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells.
    Inoue I; Goto S; Mizotani K; Awata T; Mastunaga T; Kawai S; Nakajima T; Hokari S; Komoda T; Katayama S
    Life Sci; 2000 Jul; 67(8):863-76. PubMed ID: 10946846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiinflammatory and immunomodulatory properties of statins.
    Shovman O; Levy Y; Gilburd B; Shoenfeld Y
    Immunol Res; 2002; 25(3):271-85. PubMed ID: 12018465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase inhibitors: Is the endothelium the main target?
    Puddu P; Puddu GM; Muscari A
    Cardiology; 2001; 95(1):9-13. PubMed ID: 11385185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin therapy in rheumatoid arthritis.
    Costenbader KH; Coblyn JS
    South Med J; 2005 May; 98(5):534-40; quiz 541, 572. PubMed ID: 15954510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of endothelial function in coronary microcirculation by HMG-CoA reductase drugs.
    Di Napoli P; Taccardi AA; Di Gioacchino L; De Caterina R; Barsotti A
    Ital Heart J; 2002 Jun; 3 Suppl 4():20S-23S. PubMed ID: 12116821
    [No Abstract]   [Full Text] [Related]  

  • 12. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.
    Park HJ; Kong D; Iruela-Arispe L; Begley U; Tang D; Galper JB
    Circ Res; 2002 Jul; 91(2):143-50. PubMed ID: 12142347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is LDL reduction the only effect of statins? Pleiotropic effects of statins].
    Thiery J; Brügel M
    Pharm Unserer Zeit; 2003; 32(6):472-8. PubMed ID: 14639828
    [No Abstract]   [Full Text] [Related]  

  • 14. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes].
    Cecha J; Drabek G; Błazelonis A; Romanowski W; Zubelewicz-Szkodzińska B
    Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New findings on the action of HMG-CoA-reductase inhibitors].
    Laufs U; Böhm M; Liao JK
    Dtsch Med Wochenschr; 1997 Oct; 122(41):1255-9. PubMed ID: 9378055
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions.
    Weber C; Erl W; Weber KS; Weber PC
    Clin Chem Lab Med; 1999 Mar; 37(3):243-51. PubMed ID: 10353467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of ischemia-reperfusion injury in cardiac surgery: therapeutic strategies targeting signaling pathways.
    Maeda K; Ruel M
    J Thorac Cardiovasc Surg; 2015 Mar; 149(3):910-1. PubMed ID: 25534485
    [No Abstract]   [Full Text] [Related]  

  • 18. SR-PSOX at sites predisposed to atherosclerotic lesion formation mediates monocyte-endothelial cell adhesion.
    Hofnagel O; Engel T; Severs NJ; Robenek H; Buers I
    Atherosclerosis; 2011 Aug; 217(2):371-8. PubMed ID: 21612780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do HMG-CoA reductase inhibitors prevent stroke?
    Bedi A; Flaker GC
    Am J Cardiovasc Drugs; 2002; 2(1):7-14. PubMed ID: 14727994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins and autoimmune diseases.
    Gurevich VS; Shovman O; Slutzky L; Meroni PL; Shoenfeld Y
    Autoimmun Rev; 2005 Mar; 4(3):123-9. PubMed ID: 15823497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.